FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Fricker William		 2. Issuer Name and Ticker or Trading Symbol

IMMUNOMEDICS INC [ IMMU ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Principal Accounting Officer
(Last)          (First)          (Middle)

C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD		 3. Date of Earliest Transaction (MM/DD/YYYY)

10/23/2020
(Street)

MORRIS PLAINS, NJ 07950
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)  (1)10/23/2020  D     65310   (1) (1)Common Stock 65310  (1)0 D  
Explanation of Responses:
(1) In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

Remarks:
This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of September 13, 2020, by and among Immunomedics, Inc. (the ''Company''), Gilead Sciences, Inc. (''Parent''), and Maui Merger Sub Inc., a wholly owned subsidiary of Parent (''Merger Sub''). Pursuant to the Agreement, on October 23, 2020 (the ''Effective Time''), Merger Sub merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the ''Merger''). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company (''Common Stock'') that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the ''Offer Price''), without interest and subject to required withholding taxes. A copy of the Agreement is included as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on September 14, 2020.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Fricker William
C/O IMMUNOMEDICS, INC.
300 THE AMERICAN ROAD
MORRIS PLAINS, NJ 07950

Principal Accounting Officer
Signatures
/s/ William Fricker10/27/2020
**Signature of Reporting PersonDate
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Immunomedics Charts.
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Immunomedics Charts.